rivaroxaban indications/contra

Stem definitionDrug idCAS RN
blood coagulation factor XA inhibitors, antithrombotics 4182 366789-02-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • xarelto
  • rivaroxaban
  • BAY 59-7939
A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.
  • Molecular weight: 435.88
  • Formula: C19H18ClN3O5S
  • CLOGP: 2.39
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 1
  • TPSA: 88.18
  • ALOGS: -4.64
  • ROTB: 5

Drug dosage:

DoseUnitRoute
20 mg O

Approvals:

DateAgencyCompanyOrphan
July 1, 2011 FDA JANSSEN PHARMS

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gastrointestinal haemorrhage 13824.35 41.59 3881 36236 20493 3325249
Pulmonary embolism 7761.20 41.59 2579 37538 25309 3320433
Deep vein thrombosis 7749.59 41.59 2418 37699 18971 3326771
Haemorrhage 5100.95 41.59 1735 38382 18186 3327556
Cerebrovascular accident 4799.57 41.59 1929 38188 33359 3312383
Epistaxis 3471.86 41.59 1202 38915 13249 3332493
Haemorrhage intracranial 3122.02 41.59 878 39239 4461 3341281
Haematuria 3010.50 41.59 985 39132 8967 3336775
Ischaemic stroke 3001.31 41.59 849 39268 4421 3341321
Cerebral haemorrhage 2902.75 41.59 956 39161 8898 3336844
Haemoglobin decreased 2761.08 41.59 1250 38867 29044 3316698
Thrombosis 2641.87 41.59 976 39141 13114 3332628
Anaemia 2234.60 41.59 1312 38805 53021 3292721
Haematoma 2201.08 41.59 727 39390 6812 3338930
Drug ineffective 2093.48 41.59 1683 38434 114407 3231335
Rectal haemorrhage 1960.03 41.59 704 39413 8654 3337088
Cerebral infarction 1842.40 41.59 652 39465 7648 3338094
International normalised ratio increased 1718.70 41.59 723 39394 13892 3331850
Melaena 1518.89 41.59 547 39570 6765 3338977
Upper gastrointestinal haemorrhage 1449.34 41.59 456 39661 3587 3342155
Fall 1437.75 41.59 1026 39091 57857 3287885
Subdural haematoma 1239.68 41.59 417 39700 4138 3341604
Atrial thrombosis 1233.59 41.59 287 39830 533 3345209
Incorrect dose administered 1187.82 41.59 550 39567 13364 3332378
Embolic stroke 1165.99 41.59 299 39818 977 3344765
Transient ischaemic attack 1072.18 41.59 462 39655 9409 3336333
Haemoptysis 871.14 41.59 357 39760 6374 3339368
Lower gastrointestinal haemorrhage 864.46 41.59 253 39864 1504 3344238
Haemorrhagic stroke 856.32 41.59 259 39858 1753 3343989
Contusion 841.89 41.59 446 39671 14564 3331178

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC B01AF01 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Direct factor Xa inhibitors
MeSH PA D000925 Anticoagulants
MeSH PA D000991 Antithrombins
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D065427 Factor Xa Inhibitors
MeSH PA D006401 Hematologic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D015842 Serine Proteinase Inhibitors
CHEBI has role CHEBI:50249 anticoagulant
FDA EPC N0000175637 Factor Xa Inhibitor

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Prevention of deep vein thrombosis indication 439993001
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Kidney disease contraindication 90708001 DOID:2527
Local anesthetic intrathecal block contraindication 231249005
Disease of liver contraindication 235856003 DOID:409
Procedure on spine contraindication 238181003
Lumbar puncture contraindication 277762005
Significant Bleeding contraindication
Placement of Epidural Catheter contraindication

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.89 acidic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETON OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 TREATMENT OF PULMONARY EMBOLISM (PE)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 TREATMENT OF PULMONARY EMBOLISM (PE)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7592339 Dec. 11, 2020 TREATMENT OF PULMONARY EMBOLISM (PE)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7157456 Aug. 28, 2024 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 7157456 Aug. 28, 2024 TREATMENT OF PULMONARY EMBOLISM (PE)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7157456 Aug. 28, 2024 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7157456 Aug. 28, 2024 TREATMENT OF PULMONARY EMBOLISM (PE)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7157456 Aug. 28, 2024 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 7157456 Aug. 28, 2024 TREATMENT OF PULMONARY EMBOLISM (PE)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETON OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 TREATMENT OF PULMONARY EMBOLISM (PE)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 TREATMENT OF PULMONARY EMBOLISM (PE)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9415053 Nov. 13, 2024 TREATMENT OF PULMONARY EMBOLISM (PE)
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
15MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
20MG XARELTO JANSSEN PHARMS N022406 Nov. 4, 2011 RX TABLET ORAL 9539218 Feb. 17, 2034 TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG XARELTO JANSSEN PHARMS N022406 July 1, 2011 RX TABLET ORAL Oct. 27, 2020 NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Coagulation factor X Enzyme INHIBITOR Ki 9.40 CHEMBL CHEMBL
Suppressor of tumorigenicity 14 protein Enzyme Ki 5.47 CHEMBL
Coagulation factor X Enzyme IC50 6.29 CHEMBL

External reference:

scroll-->
IDSource
C3159309 UMLSCUI
6388 IUPHAR_LIGAND_ID
D07086 KEGG_DRUG
442031002 SNOMEDCT_US
442539005 SNOMEDCT_US
1114195 RXNORM
26019 MMSL
d07356 MMSL
012873 NDDF
4030906 VANDF
N0000182971 NDFRT
N0000191960 NDFRT
9NDF7JZ4M3 UNII
8428 INN_ID
CHEMBL198362 ChEMBL_ID
DB06228 DRUGBANK_ID
9875401 PUBCHEM_CID
D000069552 MESH_DESCRIPTOR_UI
CHEBI:68579 CHEBI
RIV PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Xarelto HUMAN PRESCRIPTION DRUG LABEL 1 50458-578 TABLET, FILM COATED 15 mg ORAL NDA 20 sections
Xarelto HUMAN PRESCRIPTION DRUG LABEL 1 50458-579 TABLET, FILM COATED 20 mg ORAL NDA 20 sections
Xarelto HUMAN PRESCRIPTION DRUG LABEL 1 50458-580 TABLET, FILM COATED 10 mg ORAL NDA 20 sections
XARELTO HUMAN PRESCRIPTION DRUG LABEL 2 50458-584 KIT 15 mg None NDA 20 sections
XARELTO HUMAN PRESCRIPTION DRUG LABEL 2 50458-584 KIT 20 mg None NDA 20 sections
Xarelto HUMAN PRESCRIPTION DRUG LABEL 1 55154-1422 TABLET, FILM COATED 10 mg ORAL NDA 20 sections
Xarelto HUMAN PRESCRIPTION DRUG LABEL 1 55154-1423 TABLET, FILM COATED 20 mg ORAL NDA 20 sections
Xarelto HUMAN PRESCRIPTION DRUG LABEL 1 55154-1424 TABLET, FILM COATED 15 mg ORAL NDA 20 sections
Xarelto HUMAN PRESCRIPTION DRUG LABEL 1 69189-0578 TABLET, FILM COATED 15 mg ORAL NDA 20 sections